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Efforts of cancer research have yielded sig-
nificant advance in our understanding on 
the complexity of cancer during the past 
several decades. It is generally accepted 
that cancer development is a multi-step 
and multigenic event (Hahn and Weinberg, 
2002). The hallmarks of cancer comprise 
a series of genetic and epigenetic gain- 
and loss-of-functions of oncogenes and 
tumor suppressor genes, respectively, that 
render cancer cells capable of unrestricted 
replication potential, resistance to pro-
apoptotic stimuli, sustained angiogenesis, 
self-sufficiency in growth signals, insensi-
tivity of growth suppressor signals, evasion 
of immune surveillance, energy metabolism 
reprogramming, and acquisition of tumor-
promoting inflammation (Hanahan and 
Weinberg, 2011). With the explosion of 
knowledge on genes and molecular path-
ways that govern those cancer hallmarks, 
mechanism-based target-specific therapies 
have been developed. The rapidly emerging 
role of targeted therapies may be considered 
one of the most remarkable developments 
in the field of cancer research and therapeu-
tics over the past several decades.
Most of the target-specific drugs have 
hitherto been designed to cripple proteins 
or molecular pathways that are thought to 
be the Achilles’ heel of cancer. If the targeted 
genes or pathways are genuinely indispensa-
ble for the tumors, their inhibition should 
impede tumor propagation and progression. 
The target-specific “smart bombs” in theory 
should discriminatingly destroy cancer 
cells and leave the normal cells untouched. 
The very first two drugs of this kind are 
trastuzumab/Herceptin, a humanized 
monoclonal antibody against HER2/neu 
receptor (Baselga et al., 1998) and Imatinib, 
a BCR–ABL inhibitor (Druker et al., 2001). 
CML patients with BCR–ABL fusion pro-
tein and metastatic breast cancer patients 
with HER2/neu amplification showed 
improved response and survival rates to 
imatinib and trastuzumab respectively 
(Baselga et al., 1998; Druker et al., 2001). 
Unfortunately, following initial promising 
responses, resistance is often inevitable due 
to  mechanisms, such as secondary muta-
tions of the targets (Gorre et al., 2001) and 
activation of bypass pathways (Jones and 
Buzdar, 2009). A thorough understanding 
of the resistance mechanisms will facilitate 
the development of more effective drugs.
In the recent past, targeting addictive 
oncoproteins, such as receptor tyrosine 
kinases, has overwhelmingly led drug 
development in the field of cancer target-
specific therapies. The concept of targeting 
non-oncogene addiction has been investi-
gated as an alternative anti-cancer therapy 
(Luo et al., 2009). Proteins, such as protein 
chaperone Hsp90 and proteasomes, them-
selves are not oncogenes as they have rarely 
been found mutated or amplified in tumor 
cells. Many oncogenic proteins are often 
over-produced, unfolded or misfolded due 
to their amplification, mutations, abnormal 
epigenetic, or post-translational modifica-
tions, etc., in tumor cells. As a result, cancer 
cells become addictive to Hsp90 and protea-
somal functions for survival as the latter are 
required to fold the misfolded oncoproteins, 
which otherwise will be destroyed through 
the ubiquitination-dependent proteasome 
degradation pathways (Whitesell and 
Lindquist, 2005). Many Hsp90 and protea-
some inhibitors have been generated and 
showed some inhibitory effects on various 
cancer types in preclinical and clinical set-
tings (Rajkumar et al., 2005; Trepel et al., 
2010). More potent and less toxic inhibitors 
are being actively pursued. A major chal-
lenge in this field will be to identify the right 
cancer patients whose cancer cell survival is 
Hsp90- or proteasome-dependent, and to 
hit the targets right and hard in time with 
those inhibitors.
The concept of “metabolic reprogram-
ming or transformation” has emerged as 
the 7th hallmark of cancer during the past 
decade (Hanahan and Weinberg, 2011). 
Many studies suggest that the metabolic 
reprogramming is required for cancer cell 
survival and thus might be a good target for 
anti-cancer therapies (Tennant et al., 2010). 
The observation that cancer cells show 
increased rate of glycolysis can be traced 
back to as early as 1920s (Warburg, 1923). 
Increased glycolysis under both aerobic and 
anaerobic conditions promotes diversion 
from intracellular glucose to pyruvate, ATP, 
and NADH that in turn facilitate biosynthe-
sis of nucleosides and amino acids required 
for rapid cancer cell growth and survival. 
Since most of the enzymes and proteins 
in the glycolysis pathway are ubiquitously 
expressed in the body, caution must be paid 
to selectively target tumor-specific proteins 
or enzyme isoforms in metabolic addiction-
based target-specific therapy. Glucose trans-
porter 1 (GLUT1) which is upregulated and 
promotes glucose import into the cells, and 
hexokinase which controls the first step of 
glycolysis and is upregulated by both HIF 
and Myc in many cancer types, have been 
explored as targets for anti-cancer therapies 
(Tennant et al., 2010). Challenge remains 
as to the identification of tumor type 
specific metabolic pathways so that bona 
fide tumor-specific targets may be used 
to develop more efficacious and less toxic 
drugs for metabolic addiction-based target-
specific therapies.
Different molecular networks can steer 
or buffer overlapping cellular processes, 
and disruption of one network can lead 
to an acquired dependency on another. An 
example of this is synthetic lethal interac-
tion described in yeast and fruit fly, in which 
perturbation of two genes causes cell death 
(synthetic lethal) whereas perturbation of 
either gene alone exerts minimal or no effect 
on cell survival (Lucchesi, 1968; Hartman 
et al., 2001). With the discovery of RNA 
interference (RNAi), the synthetic lethal 
interaction idea has recently been adopted 
for unbiased screen for synthetic lethal 
partners of frequently mutated but phar-
macologically non-inhibitable genes, such 
as Ras, or tumor suppressor genes (PTEN, 
P53, VHL, APC, BRCA, etc.) that are deleted 
in tumors and thus cannot be targeted 
(Kaelin, 2005; Kuiken and Beijersbergen, 
2010). This approach will undoubtedly lead 
to the discovery of novel drug targets and 
mechanisms of network addiction in cancer 
cells. It may also open an alternative way 
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With this in mind, understanding cancer 
molecular networks, heterogeneity, and 
the nature of cancer evolution will be of 
paramount importance in directing future 
target-specific therapeutics and evading 
resistance.
One of the most formidable challenges 
in anti-cancer drug development in the past 
decade has been the amazing number of 
clinical drug candidates that have emerged. 
Having phase I testing of all these drugs has 
become a major hurdle and prioritization 
has therefore become essential. A typi-
cal example is the field of tyrosine kinase 
inhibitors with inhibitors that target sev-
eral similar and partially overlapping path-
ways. Furthermore, the presence of multiple 
genetic alterations in common tumors, that 
can act as oncogenic drivers, clearly points 
to the necessity of using combinations of 
multiple drugs with multiple mechanisms 
of action, with drugs that should poten-
tially have little overlapping toxicities. The 
use of more predictive preclinical models 
to test single agents and combinations has 
been partially addressed by genetically 
engineered mouse models and orthotopic 
models, but we are still far from optimal 
prediction of efficacy in humans. Changing 
in design of phase I trials, with extension 
phases to assess preliminary activity in 
enriched populations, the increased use of 
randomized phase II studies before embark-
ing in phase III testing and the introduc-
tion of biomarkers early in development, 
in order to select patient populations 
more prone to respond to treatment, all 
have been taken place at a very rapid pace 
in recent years. With the rapid growing 
momentum of new technologies, such as 
the next-generation sequencing, proteom-
ics, and functional genomics, that allow to 
examine every molecule of a cancer cell at 
unprecedented speed and cost– effective 
manner, it is foreseeable that knowledge on 
molecular networks and heterogenic regu-
lations of cancer will be the next wave of 
explosion. Cancer target-specific therapies 
will heavily rely on the innovative ideas and 
technologies to uncover the real Archille’s 
heel of cancer. In the next several decades 
to come, we envision that combination of 
mechanism-based discretionary targeting 
of several core pathways vital for tumor 
survival may bear significant fruits in cur-
ing cancers and evading drug resistance. We 
anticipate that we will be able to find much 
suggest that CSC niche, composed of stro-
mal cells, blood vessels, and extracellular 
matrix components, plays crucial roles in 
controlling CSC self-renewal, differentia-
tion, epithelial–mesenchymal-transition, 
invasion, and metastasis (Borovski et al., 
2011). Future CSC target therapy should 
include targeting and blocking of CSC 
niche signaling and interaction with CSCs 
for more effective eradication of CSCs 
(Borovski et al., 2011).
Other areas under fierce development 
in the field of target-specific therapeutics 
include exploration of innovative strategies 
to reactivate tumor suppressors and inhibit 
oncogenic transcription factor complexes. 
An example of the former is the discovery 
and characterization of small molecules 
that reverse the epigenetic silencing of 
RASSF1A tumor suppressor protein in 
preclinical models (Sheikh et al., 2010). 
Unlike enzymes, transcriptional factors are 
generally entailed “undruggable”. Strategies 
to disrupt protein–protein interactions 
and post-translational modifications of 
oncogenic transcription factor complexes 
have drawn significant attention recently 
(Gorczynski et al., 2007; Erkizan et al., 
2009). Last but not least, there are great 
demands for innovative ideas to develop 
novel vehicles carrying drugs specifi-
cally into the tumors and more efficiently 
through blood brain barriers.
It is disappointing to concede that resist-
ance is almost a universal rule following 
initial encouraging response in most of the 
targeted therapeutic trials to date. One of 
the potential mechanisms of resistance is 
the presence of dormant tumor cells since 
most of the radio-, chemo-, and target- 
therapies rely on cell division and work only 
against replicating but not quiescent cells 
(Konopleva and Jordan, 2011). Another 
possibility is that multiple partially redun-
dant pathways may prevail in tumor cells, 
and when one pathway is inhibited, tumor 
cells adopt other redundant pathway(s) 
to sustain their growth (Hanahan and 
Weinberg, 2011). The third possibility is 
that cancer cells may be constantly evolving 
and target-specific inhibition of one path-
way leads to de novo activation of another 
pathway(s) that keep(s) cancer cells alive. 
Still other mechanisms of resistance may 
be attributed to differences in pharmacog-
enomics, metabolism, and intratumoral 
drug exposure among individual patients. 
to effectively treat tumors carrying those 
“non-druggable” genes. Another attractive 
aspect of synthetic lethality screen is that it 
may accelerate the search for regulators of 
target-specific inhibitor resistance in can-
cer cells. Erlotinib-treated cancer cells have 
been subjected to synthetic lethal screen 
with a library containing >600 selected 
siRNAs against putative EGFR interact-
ing proteins. Inhibition of PRKC, Aurora 
A, and Stat3 were found synthetic lethal 
with erlotinib in many erlotinib-resistant 
cell lines, indicating they may be potential 
regulators of resistance and have significant 
clinical implications in EGFR-targeted ther-
apy (Astsaturov et al., 2010). The advance-
ment of synthetic lethal screen has fueled 
the expectation toward new discoveries of 
novel biomarkers, targets, and molecular 
pathways for cancer diagnosis and therapy. 
To meet these expectations, in the years to 
come, we wish to see the improvement of 
not only RNAi technologies but also high-
throughput target validations to eliminate 
false positive discoveries.
Increasing evidence suggests that cancer 
stem cells (CSCs) are more resistant than 
other cells to conventional radiotherapy, 
chemotherapy and most of the target-
specific therapies, though many aspects of 
CSC hypothesis remain speculative and are 
still evolving (Zhou et al., 2009). Potential 
mechanisms of the resistance can be attrib-
uted to the observation that CSCs are in 
quiescent state (Konopleva and Jordan, 
2011), resistant to DNA damage and express 
high levels of ABC drug pumps and anti-
apoptotic proteins (Zhou et al., 2009). CSCs 
that have not been eradicated can lead to 
recurrence of cancer later. Thus, regimens 
or drugs that eliminate CSCs independ-
ent of cell cycle status may be an attrac-
tive strategy in drug development, such as 
targeting gene products and pathways, for 
example, the Hedgehog, Notch, and Wnt 
pathways among others that are activated in 
CSCs (Konopleva and Jordan, 2011). Based 
on data derived from a mouse model of 
human acute myeloid leukemia stem cells, 
it has been proposed that induction of 
leukemia stem cell cycle entry before treat-
ment with conventional chemotherapy may 
be feasible (Saito et al., 2010). Elucidation 
of the molecular mechanisms underlying 
the maintenance of CSC quiescence will 
undoubtedly facilitate the future CSC tar-
get therapies. Increasing bodies of evidence 
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better cancer specific biomarkers for early 
diagnosis and prognostic prediction, and 
to treat each patient based on his/her own 
tumor-specific molecular identities.
This journal is open to contributions in 
the field discovery of cancer target-specific 
treatments, some of which have been briefly 
described above. The journal will be an 
open forum for the publication of novel 
strategies for cancer treatment and novel 
technologies to identify and characterize 
potential new targets.
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